Nuvectis Pharma, Inc. Common Stock
NVCTNuvectis Pharma, Inc. is a biopharmaceutical company focused on developing targeted medicines for the treatment of cancer and other serious conditions. The company specializes in leveraging precision medicine approaches to address unmet medical needs, particularly in the fields of oncology and rare diseases.
Company News
Nuvectis Pharma (Nasdaq: NVCT), a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 5 million shares at $20.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to advance development of its pipeline candidates NXP100, NXP200, and NXP900, hire personnel, an...
Nuvectis Pharma announced three poster presentations for its clinical-stage drug NXP900, a first-in-class YES1/SRC inhibitor, at the 2026 AACR Meeting in San Diego (April 17-22). The presentations will showcase NXP900's synergy with KRAS inhibitors in NSCLC models, strategies to overcome drug resistance in cholangiocarcinoma, and its potential to...
Nuvectis Pharma, a clinical-stage biopharmaceutical company, announced the pricing of its $13.5 million public offering of 2.7 million shares of common stock at $5 per share. The company plans to use the proceeds to advance the development of its drug candidates NXP800 and NXP900.
Nuvectis Pharma, Inc. reported its Q3 2024 financial results and provided updates on the development of its drug candidates NXP800 and NXP900. The company expects a clinical data update for NXP800 this month and has progressed the NXP900 Phase 1a study with no dose-limiting toxicities.
Nuvectis Pharma announced that the FDA granted Orphan Drug Designation for its drug candidate NXP800 to treat a subset of ovarian cancer with ARID1a deficiency. This designation provides financial incentives and potential marketing exclusivity if the drug is approved.
